Kite Pharma (Gilead) and their CAR-T therapy Yescarta violated a patent from Memorial Sloan Kettering Cancer Center (MSKCC), which was licensed to BMS’ Juno Therapeutics and to MSKCC. A federal jury finds Kite must pay $752 million. Gilead paid $11.9 billion for the...
TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.
159 WEST BROADWAY SUITE 200 SALT LAKE CITY, UT 84101
Pin It on Pinterest